CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies. Issue 23 (June 2018)

• Record Type: Journal Article
• Authors: Huang, Rongyong; Mo, Dan; Wu, Junrong; Ai, Huaying; Lu, Yiping
• Other Names: Augustin. Goran section editor.
• Is Part Of: Medicine. Volume 97:Issue 23(2018)
• Publication Date: 2018-06
• Subjects: CD133 -- colorectal cancer -- prognosis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000010446
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: CD133 has been identified as a putative cancer stem cell marker in colorectal cancer (CRC). However, the clinicopathological and prognostic significance of CD133 in CRC patients remains controversial. Thus, we conducted a meta-analysis to quantitatively evaluate the above issues. Methods: We collected a comprehensive literature search from PubMed, Web of Science, and Embase database up to September 20, 2016 examining CD133 and clinical features of colorectal cancer patients. We used the odds ratio (OR) with 95% confidence interval (CI) to estimate the effects by overall and stratified analysis. Results: The overall result of our meta-analysis indicated that CD133 expression was positively correlated with T category, distant metastasis, lymphatic invasion, and vascular invasion. Moreover, patients with higher CD133 expression had a poorer overall survival (OS) (HR=2.01, P < .001) and a lower 5-year OS rate (OR = 3.26, P < .001) than those with lower expression. Disease-free survival (DFS) and 5-year DFS rate were similar with the above results. Though the correlation between CD133 expression with the clinical characteristic was not positive in some ways when we analyzed the different subgroup. The prognostic value of CD133 expression for 5-year OS rate of CRC patients was noticeable in spite of different patients' region, multiple antibodies used in studies, various cut-off values of CD133 expression, and adjuvant therapy situation of patients. Conclusion: CD133 is a useful predictive or prognostic biomarker for CRC in clinical assessment and may serve as a potential therapeutic target for CRC.